Literature DB >> 21075437

Ovarian cancer patient surveillance after curative-intent initial treatment.

Garo Z Harmandayan1, Feng Gao, David G Mutch, Katherine S Virgo, Randall K Gibb, Frank E Johnson.   

Abstract

OBJECTIVE: Patient surveillance after potentially curative treatment of ovarian carcinoma has important clinical and financial implications for patients and society. The optimal intensity of surveillance for these patients is unknown. We aimed to document the current follow-up practice patterns of gynecologic oncologists.
METHODS: We created four idealized vignettes describing patients with stages I-III ovarian cancer. We mailed a custom-designed survey instrument based on the vignettes to the members of the Society of Gynecologic Oncologists (SGO). SGO members were asked, via this instrument, how often they requested 11 discrete follow-up evaluations for their patients for the first 10 postoperative years after treatment with curative intent.
RESULTS: We received 283 evaluable responses (30%) from the 943 SGO members and candidate members. The most frequently performed items for each year were office visit, pelvic examination, and serum CA-125 level. Imaging studies such as chest X-ray, abdominal-pelvic CT, chest CT, abdominal-pelvic MRI, and transvaginal ultrasound were rarely recommended. There was marked variation in the frequency of use of most tests. There was a decrease in the frequency of testing over time for all modalities.
CONCLUSION: This dataset provides detailed documentation of the self-reported surveillance practices of highly credentialed experts who manage patients with ovarian cancer in the 21st century. The optimal follow-up strategy remains unknown and controversial. Our survey showed marked variation in surveillance intensity. Identifying the sources of this variation warrants further research.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21075437     DOI: 10.1016/j.ygyno.2010.10.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study.

Authors:  Jacqueline Feinberg; Karen Carthew; Emily Webster; Kaity Chang; Nita McNeil; Dennis S Chi; Kara Long Roche; Ginger Gardner; Oliver Zivanovic; Yukio Sonoda
Journal:  Int J Gynecol Cancer       Date:  2021-12-29       Impact factor: 3.437

2.  A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.

Authors:  Aasthaa Bansal; Patrick J Heagerty; Lurdes Y T Inoue; David L Veenstra; Charles J Wolock; Anirban Basu
Journal:  Med Decis Making       Date:  2021-11-07       Impact factor: 2.583

3.  Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125.

Authors:  Takamichi Minato; Shin Ito; Bin Li; Haruna Fujimori; Mai Mochizuki; Kazunori Yamaguchi; Keiichi Tamai; Muneaki Shimada; Hideki Tokunaga; Shogo Shigeta; Ikuro Sato; Hiroshi Shima; Hidekazu Yamada; Nobuo Yaegashi; Jun Yasuda
Journal:  Gynecol Oncol Rep       Date:  2021-08-17

4.  Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Authors:  Katharine M Esselen; Angel M Cronin; Kristin Bixel; Michael A Bookman; Robert A Burger; David E Cohn; Mihaela Cristea; Jennifer J Griggs; Charles F Levenback; Gina Mantia-Smaldone; Larissa A Meyer; Ursula A Matulonis; Joyce C Niland; Charlotte Sun; David M O'Malley; Alexi A Wright
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.